RT info:eu-repo/semantics/article
T1 Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry
A1 Coco Martín, María Begoña
A1 Leal Vega, Luis
A1 Blázquez Cabrera, José Antonio
A1 Navarro, Amalia
A1 Moro, María Jesús
A1 Arranz García, Francisca
A1 Amérigo, María José
A1 Sosa Henríquez, Manuel
A1 Vázquez, María Ángeles
A1 Montoya, María José
A1 Díaz Curiel, Manuel
A1 Olmos, José Manuel
A1 Ruiz Mambrilla, Marta María
A1 Filgueira Rubio, José
A1 Pérez Castrillon, José Luis
A1 Hernández de Sosa, Nerea
A1 Calero Bernal, María Luz
A1 Armengol Sucarrats, Dolors
A1 Escalante Yanguas, Begoña de
A1 Miranda Díaz, Cristina
A1 Miranda García, María José
A1 Giner García, Mercedes
A1 Jareño Chaumel, Julia
A1 Cotos Canca, Rafael
A1 Hernández, José Luis
A1 Rodero Hernández, Francisco Javier
A1 Sánchez Molini, Pilar
A1 Aguado Caballero, José María
A1 Cobeta García, Juan Carlos
A1 Tirado Miranda, Raimundo
K1 Osteoporosis
K1 Fractures
K1 Prescription drugs
K1 Cohort analysis
K1 Logistic models
K1 32 Ciencias Médicas
AB Purpose To evaluate the effect of different non-osteoporotic drugs on the increase or decrease in the risk of incident fragilityfractures (vertebral, humerus or hip) in a cohort of patients diagnosed with osteoporosis on active anti-osteoporotic therapy.Methods For this retrospective longitudinal study, baseline and follow-up data on prescribed non-osteoporotic treatmentsand the occurrence of vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzedusing logistic regression models. The drugs evaluated with a possible beneficial effect were thiazides and statins, while thedrugs evaluated with a possible harmful effect were antiandrogens, aromatase inhibitors, proton pump inhibitors, selectiveserotonin reuptake inhibitors, benzodiazepines, GnRH agonists, thyroid hormones, and oral and inhaled corticosteroids.Results Logistic regression analyses indicated that no treatment significantly improved fracture risk, with the only treatmentsthat significantly worsened fracture risk being letrozole (OR = 0.18, p-value = 0.03) and oral corticosteroids at doses ≤ 5 mg/day (OR = 0.16, p-value = 0.03) and > 5 mg/day (OR = 0.27, p-value = 0.04).Conclusion The potential beneficial or detrimental effects of the different drugs evaluated on fracture risk are masked bytreatment with anabolic or antiresorptive drugs that have a more potent action on bone metabolism, with two exceptions:letrozole and oral corticosteroids. These findings may have important clinical implications, as patients receiving these treat-ments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs suchas denosumab or teriparatide.
PB Springer
SN 0031-6970
YR 2023
FD 2023
LK https://uvadoc.uva.es/handle/10324/61602
UL https://uvadoc.uva.es/handle/10324/61602
LA eng
NO European Journal of Clinical Pharmacology, 2023, vol. 79, n. 10, p. 1333-1339.
NO Producción Científica
DS UVaDOC
RD 26-dic-2024